Targeting ATM in tumours rich in myofibroblastic cancer-associated fibroblasts enhance CD8+ T-cell infiltration and improves responsiveness to immunotherapeutic interventions, providing a compelling rationale for combining ATM inhibitors with immune checkpoint blockade therapies. This evidence concerns the gene ATM and cancer.